Table 3. Relationship between Biomarkers of Inflammation/ Immune Activation with Free Testosterone.
The first column in the table shows the effects of HIV-status and time of blood draw in a fully adjusted mixed effects regression model†. Each subsequent column shows the same effect estimates with the inclusion of a biomarker in the regression model. The effect estimates of the biomarker on FT (per doubling of biomarker) are also given.
| Models† | No biomarkers Estimate (95% CI) |
With gp130 Estimate (95% CI) |
With MCP1 Estimate (95% CI) |
With CD14 Estimate (95% CI) |
With sTNFr2 Estimate (95% CI) |
With BAFF Estimate (95% CI) |
With IL6 Estimate (95% CI) |
With TARC Estimate (95% CI) |
With CRP Estimate (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Effects | |||||||||
| HIV+ vs. HIV− in AM samples (at mean age 52) | −10.3* (−17.6, −3.0) |
−9.8* (−17.1, −2.5) |
−8.5* (−15.9, −1.1) |
−8.6* (−16.0, −1.1) |
−8.4* (−15.9, −1.0) |
−9.0* (−16.5 −1.6) |
−9.7* (−17.1, −2.3) |
−9.6* (−17.0, −2.3) |
−9.5* (−16.9, −2.1) |
| HIV+ vs. HIV− in PM samples (at mean age 52) | −1.6 (−10.1, 6.8) |
−0.9 (−9.4, 7.6) |
−0.5 (−8.9, 8.0) |
−0.4 (−8.9, 8.2) |
1.2 (−7.4, 9.8) |
−0.4 (−9.0, 8.1) |
−1.3 (−9.7, 7.2) |
−0.9 (−9.3, 7.6) |
−1.2 (−9.8, 7.4) |
| HIV−, age (per 10-year) | −10.9 * (−19.3, −2.6) |
−11.3* (−19.6, −2.9) |
−10.8* (−19.1, −2.4) |
−10.9* (−19.3, 2.6) |
−11.2* (−19.6, −2.9) |
−10.9* (−19.2, −2.5) |
−10.2* (−18.6, −1.9) |
−11.4* (−19.7, −3.0) |
−10.8* (−19.2, 2.5) |
| HIV+, age (per 10-year) | −9.1* (−13.3, −4.9) |
−9.0* (−13.2, −4.9) |
−9.2* (−13.4, 5.0) |
−9.1* (−13.3, −4.9) |
−8.5* (−12.7, −4.2) |
−9.0* (−13.2, −4.7) |
−8.1* (−12.3, −3.8) |
−9.0* (−13.2, −4.8) |
−8.5* (−12.8, −4.2) |
| HIV−, PM (vs. AM) | −10.4* (−20.4; −0.5) |
−10.4* (−20.3, −0.5) |
−9.9* (−19.8, −0.1) |
−10.0* (−19.9, −0.1) |
−11.4* (−21.3, −1.5) |
−10.3* (−20.2, −0.4) |
−10.5* (−20.5, −0.6) |
−10.8* (−20.7, −0.8) |
−10.3* (−20.4, −0.3) |
| HIV+, PM (vs. AM) | −1.8 (−5.9, 2.4) |
−1.5 (−5.7, 2.6) |
−1.9 (−6.0, 2.2) |
−1.8 (−5.9, 2.3) |
−1.8 (−5.9, 2.3) |
−1.7 (−5.8, 2.5) |
−2.1 (−6.1, 2.0) |
−2.0 (−6.1, 2.2) |
−2.0 (−6.1, 2.2) |
| Biomarkers (per 1 log2) | |||||||||
| gp130 | - | −5.5* (−10.6; −0.3) |
- | - | - | - | - | - | - |
| MCP1 | - | - | −4.9* (−8.3; −1.5) |
- | - | - | - | - | - |
| CD14 | −4.6* (−8.9; −0.2) |
- | |||||||
| sTNFr2 | - | - | - | - | −4.5* (−7.4, −1.6) |
- | - | - | |
| BAFF | - | - | - | −3.3 * (−6.3, −0.3) |
|||||
| IL6 | - | - | - | - | - | - | −2.5* (−3.8; −1.2) |
- | - |
| TARC | - | - | - | - | - | - | - | −1.9* (−3.7, −0.03) |
- |
| CRP | - | - | - | - | - | - | - | - | −1.1* (−2.1; −0.05) |
*
p<0.05
†
All models included following factors: HIV-serostatus, age, race, MACS center, smoking status, BMI, HCV serostatus, cumulative years on HAART among HIV-infected men, time of day of blood draw, total number of comorbidities, the interaction of HIV-status * age, and the interaction of HIV-status * time of blood drawn.